Roche Holding AG (RO SW) stock market data APIs
CHF272.2297
-4.34(-1.6%)
as of April 17, 2025
Roche Holding AG Financial Data Overview
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and others; diagnostic instruments; and digital health solutions. The company was founded in 1896 and is based in Basel, Switzerland.
Prev. Close
272.2297
Open
267.8859
High
276.5229
Low
266.1163
52 wk Range
225.3773-323.5192
Market Cap
204 819 M
P/E Ratio
26.1688
Shares Outstanding
107 M
Revenue
62 395 M
EPS
0
Dividends (Yield)
0.036
Beta
0.216
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Roche Holding AG data using free add-ons & libraries
Get Roche Holding AG Fundamental Data
Roche Holding AG Fundamental data includes:
- Net Revenue: 62 395 M
- EBITDA: 22 717 M
- Earnings Per Share: 10
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2024-04-26
- EPS/Forecast: 0
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Roche Holding AG News
New
Stocks to watch next week: Tesla, Alphabet, Intel, Boeing and Unilever
As the latest earnings season gets well underway, there are a range of big-name companies due to report in the coming week. Two Magnificent 7 companies are reporting next week, with Elon Musk's Tesla...
Pharma Stock Roundup: J&J's Q1 Results, PFE's Obesity Setback
J&J JNJ began the earnings season for the drug and biotech sector this week. Pfizer PFE announced the discontinuation of its danuglipron weight loss pill program. The European Commission granted marke...
Roche Gets Nod for Expanded Use of Columvi in Lymphoma in Europe
Roche RHHBY announced that the European Commission has approved its lymphoma drug, Columvi (glofitamab), for second-line treatment of relapsed or refractory (R/R) diffuse large B-cell lymphoma (“DLB...
European Commission approves Roche’s Columvi as the first bispecific antibody for diffuse large B-cell lymphoma after initial therapy
F. Hoffmann-La Roche Ltd Approval based on Phase III STARGLO study where Columvi in combination with chemotherapy showed a 41% reduction in the risk of death compared to MabThera/Rituxan plus chemoth...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
